Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MGC026 Dose Escalation
MGC026 · 1 trial · 22 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | MGC026 is a topoisomerase 1 inhibitor (TOP1i)-based ADC that targets B7-H3 administered IV every 3 weeks. |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | - |
| Cohort 4 | EXPERIMENTAL | - |
| Cohort 5 | EXPERIMENTAL | - |
| Cohort 6 | EXPERIMENTAL | - |
| Expansion cohort 1 | EXPERIMENTAL | - |
| Expansion cohort 2 | EXPERIMENTAL | - |
| Expansion cohort 3 | EXPERIMENTAL | - |
| Expansion cohort 4 | EXPERIMENTAL | - |
| Expansion Cohort 5 | EXPERIMENTAL | - |
| Expansion Cohort 6 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MGC026 Dose Escalation | BIOLOGICAL | Escalating doses of MGC026 |
| MGC026 Dose for Expansion | BIOLOGICAL | MGC026 recommended dose for expansion |
Inclusion Criteria: * Adults ≥ 18 years old, able to provide informed consent * Adequate performance and laboratory parameters * Availability of archival or formalin-fixed paraffin-embedded tumor tissue sample. Participants may undergo a fresh tumor biopsy to obtain a specimen for testing if an arc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MGC026 is an investigational monoclonal antibody being studied for the treatment of advanced solid tumors, including advanced cancer, metastatic cancer, and a range of specific tumor types such as non-small cell lung cancer, melanoma, breast cancer, and colorectal cancer. It is currently in Phase 1 clinical development.
MGC026 is being developed by MacroGenics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol MGNX. The company is conducting a Phase 1 clinical trial of MGC026 in participants with advanced solid tumors.
MGC026 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is currently recruiting participants with advanced solid tumors.
MGC026 is being evaluated in a Phase 1 clinical trial with the identifier NCT06242470, titled "A Study of MGC026 in Participants With Advanced Solid Tumors." The trial is recruiting up to 250 participants in the United States, Australia, and the United Kingdom.
Yes, MGC026 Dose Escalation refers to the same drug, MGC026. The Phase 1 trial NCT06242470 is a dose escalation study designed to evaluate MGC026 in participants with advanced solid tumors, including various cancer types such as head and neck cancer, lung cancer, and ovarian cancer.